Tyra Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Dabogratinib is advancing in three late-stage indications—intermediate-risk NMIBC, UTUC, and achondroplasia—with pivotal data readouts expected in the coming year. The drug’s oral formulation and strong safety profile position it as a disruptive, best-in-class option in large, underserved markets.
-
Dabogratinib is advancing in three major indications—UTUC, NMIBC, and achondroplasia—with pivotal studies and key data readouts expected this year. The oral formulation, strong safety, and high unmet need position it for rapid adoption, especially in community practices.
-
Multiple phase II trials are advancing for dabogratinib in FGFR3-driven diseases, with a focus on intermediate risk NMIBC, UTUC, and achondroplasia. Key data readouts are expected mid- and late-year, and the pipeline remains active with ongoing FGFR3 discovery efforts.
Fiscal Year 2025
-
Dabogratinib, a selective oral FGFR3 inhibitor, is advancing in phase II trials for NMIBC, upper tract urothelial carcinoma, and achondroplasia, aiming to match or exceed current efficacy benchmarks with improved safety. Key data readouts are expected in 2025, with strong physician enthusiasm and a robust financial position supporting rapid advancement.
-
A highly selective oral FGFR3 inhibitor is advancing in phase 2 trials for NMIBC and ACH, aiming to address significant unmet needs with a differentiated safety and efficacy profile. The company is positioned to capture large market opportunities by offering a convenient, best-in-class therapy.
-
Two phase II programs for a selective FGFR3 inhibitor are advancing in NMIBC and achondroplasia, both prioritized due to strong scientific rationale and large patient populations. The oral therapy offers a favorable safety profile and convenience, with initial data expected next year and a cash runway through 2027.
-
TYRA-300, a highly selective FGFR3 inhibitor, is advancing in both skeletal dysplasia and oncology indications, aiming for superior efficacy and safety over current therapies. The BEACH301 trial in achondroplasia targets 8–8.5 cm/year growth, with initial safety and efficacy data expected next year. TYRA-300 also shows strong potential in oncology with reduced toxicity.
-
The conference highlighted a differentiated FGFR3 inhibitor platform with promising early clinical results in NMIBC and achondroplasia, aiming for superior efficacy and safety over current therapies. Strategic focus is on key phase two trials, with strong financial positioning through 2027.
-
TYRA-300, a selective FGFR3 inhibitor, shows strong efficacy and a favorable safety profile in urothelial carcinoma and achondroplasia, with phase II trials underway in NMIBC and ACH. Early data readouts are expected by early next year, with plans to expand into additional skeletal dysplasias.
-
TYRA-300 shows strong efficacy and safety in urothelial cancer and NMIBC, with lower toxicity than competitors and promising market potential. Achondroplasia and related growth disorders represent significant expansion opportunities, and a novel FGFR3/4 inhibitor for liver cancer is entering clinical trials.
Fiscal Year 2024
-
The company is advancing FGFR3-selective inhibitors to address unmet needs in bladder cancer and achondroplasia, showing improved safety and efficacy over pan-FGFR therapies. Key milestones include imminent clinical data readouts for both NMIBC and achondroplasia.
-
Lead FGFR3 inhibitor showed superior efficacy and safety in metastatic urothelial cancer, with phase 2 studies in achondroplasia and NMIBC set to begin. Early safety data and rapid readouts are expected in 2025, positioning the oral therapy as a unique competitor.
-
Interim results from the SURF301 study show TYRA-300 achieved a 54.5% clinical activity rate in mUC with a favorable safety profile and low rates of key toxicities. Dose optimization continues, with plans to expand into NMIBC and achondroplasia at lower doses.
-
A highly selective FGFR3 inhibitor is advancing through clinical trials, with first-in-human data expected this fall and plans for phase 2 in achondroplasia. The approach aims to match efficacy benchmarks while improving tolerability, addressing a large market with significant unmet needs.
-
The conference highlighted a robust pipeline targeting FGFR-driven diseases, with TYRA-300 advancing in both achondroplasia and oncology. Selectivity and resistance mutation avoidance differentiate the approach, with key clinical data and IND submissions expected in the second half of the year.